GLP-1 Drug Exendin-4 Protects Dopamine Neurons From Parkinson's-Like Damage

The GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprotective role for incretin drugs in Parkinson's-like neurodegeneration.

Kim, Sehee et al.·The Journal of endocrinology·2009·
RPEP-015052009RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprotective role for incretin drugs in Parkinson's-like neurodegeneration.

Key Numbers

How They Did This

research study.

Why This Research Matters

Relevant for peptide research.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.

Trust & Context

Key Stat:
Key finding The GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprot
Evidence Grade:
emerging evidence.
Study Age:
Published in 2009.
Original Title:
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Published In:
The Journal of endocrinology, 202(3), 431-9 (2009)
Database ID:
RPEP-01505

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

GLP-1 Drug Exendin-4 Protects Dopamine Neurons From Parkinson's-Like Damage

What was found?

The GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprotective role for incretin drugs in Parkinson's-like neurodegeneration.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-01505·https://rethinkpeptides.com/research/RPEP-01505

APA

Kim, Sehee; Moon, Minho; Park, Seungjoon. (2009). Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.. The Journal of endocrinology, 202(3), 431-9. https://doi.org/10.1677/JOE-09-0132

MLA

Kim, Sehee, et al. "Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.." The Journal of endocrinology, 2009. https://doi.org/10.1677/JOE-09-0132

RethinkPeptides

RethinkPeptides Research Database. "Exendin-4 protects dopaminergic neurons by inhibition of mic..." RPEP-01505. Retrieved from https://rethinkpeptides.com/research/kim-2009-exendin4-protects-dopaminergic-neurons

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.